Investigational drug · Phase 3
AG-236
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Polycythemia Vera.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "AG-236"
First trial start
2026
Nov 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AG-236", any sponsor or status.
Conditions studied
As listed on its trial records.
- Polycythemia Vera
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "AG-236" as an intervention, largest first.
- A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia VeraPivotal-lookingNot yet recruiting
Agios Pharmaceuticals, Inc.Industry
NCT07859423 · 245 participants (planned) · Start Nov 2026 · Primary completion Aug 2030
Drug: AG-236; Placebo · For: Polycythemia Vera
- A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy ParticipantsActive, not recruiting
Agios Pharmaceuticals, Inc.Industry
NCT07075640 · 24 participants · Start Jul 7, 2025 · Primary completion Feb 11, 2026
Drug: AG-236; Placebo · For: Healthy Participants
Sites: Madison, Wisconsin
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Polycythemia Vera
- BomedemstatMK-3543, IMG-7289Phase 35 trials
Merck & Co. · Polycythemia Vera, Essential Thrombocythemia, Thrombocythemia, Essential
- KRT-232NavtemadlinPhase 34 trials
Kartos Therapeutics, Inc. · Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
- SapablursenISIS 702843, ONO-0530Phase 32 trials
Ono Pharmaceutical Co., Ltd. · Polycythemia Vera, Phlebotomy Dependent Polycythemia Vera
- JBI-802Phase 21 trial
Jubilant Therapeutics Inc. · Essential Thrombocythemia (ET), Polycythemia Vera
- SLN124Phase 21 trial
Silence Therapeutics plc · Polycythemia Vera
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.